Summary of dose-limiting toxicities reported at each pomalidomide dose level
| Daily dose of pomalidomide . | Median number of completed treatment cycles* (range) . | Number of dose-limiting toxicities (type) . |
|---|---|---|
| 2 mg (n = 6) | 1.5 (1-12) | 1 (grade 3 fatigue) |
| 3 mg (n = 8) | 5.0 (2-13) | 1 (grade 4 neutropenia) |
| 4 mg (n = 14) | 5.5 (1-30) | 2 (grade 4 neutropenia) |
| 5 mg (n = 10) | 8.0 (1-26) | 3 (grade 4 neutropenia) |
| 1 (grade 3 neutropenia) |
| Daily dose of pomalidomide . | Median number of completed treatment cycles* (range) . | Number of dose-limiting toxicities (type) . |
|---|---|---|
| 2 mg (n = 6) | 1.5 (1-12) | 1 (grade 3 fatigue) |
| 3 mg (n = 8) | 5.0 (2-13) | 1 (grade 4 neutropenia) |
| 4 mg (n = 14) | 5.5 (1-30) | 2 (grade 4 neutropenia) |
| 5 mg (n = 10) | 8.0 (1-26) | 3 (grade 4 neutropenia) |
| 1 (grade 3 neutropenia) |
Use of G-CSF was not allowed during the first 28 days (cycle 1) of the phase 1 study.